Lymphoma is a tumor originating from lymph nodes or other lymphatic tissues. Lymphoma includes not only the traditional non-Hodgkin’s lymphoma and Hodgkin’s lymphoma, but also multiple myeloma, acute lymphoblastic leukemia, and various lymphoproliferative diseases according to the new WHO lymphoma classification in 2008. The most common ones are painless lymph node enlargement in the supraclavicular fossa, neck and axilla and tonsillar enlargement, especially after anti-infection treatment, the lymph nodes are further enlarged. The more typical manifestations are the so-called “B symptoms”, i.e. irregular fever, night sweats and emaciation. Lymphoma has three characteristics: 1. Complexity: As of 2008 WHO classification of lymphoma, there are 43 subtypes of lymphoma, and each subtype of lymphoma has obvious differences in pathological structure, immunophenotyping, cytogenetics and molecular biology expression, and the treatment plan and treatment protocols are all different; 2. 3. Irregular diagnosis and treatment: Most non-specialist doctors lack knowledge of lymphoma and cannot diagnose and treat lymphoma at an early stage, and cannot apply standard treatment plans, so many patients who could be cured cannot be treated effectively. The key to overcome lymphoma: 1. Early diagnosis and standardized treatment: Most of the patients with stage I and II lymphoma have very good efficacy if they adopt standardized treatment, while late detection, irregular treatment plan and insufficient treatment dose will affect the long-term efficacy and cure rate; 2. Full course of treatment: Some patients stop treatment after one or two courses of treatment, which greatly affects the efficacy. The cornerstone of curative effect is a full course of treatment (the course of treatment varies from patient to patient); 3. Proper selection of hospital: The hospital of choice should at least have the following conditions: capable of conducting comprehensive pathology, immunohistochemistry, cytogenetics and molecular biology diagnosis, complete drugs, treating physicians with a deep understanding of lymphoma, and capable of applying standardized chemotherapy protocols and targeted therapy.